This clinical trial showed that, despite the rate of PEPI scored 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, patients with HER2-negative breast cancer. Here, ERBB2 is linked to breast carcinoma.